Navigation Links
Boston Scientific's TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
Date:9/22/2010

er density alloy provides superior visibility and reduced recoil while permitting thinner struts compared to prior-generation stents(3).

"We are pleased to see the strong performance of the TAXUS Element Stent in both the overall population of the PERSEUS trial and the diabetic patient subset," said Hank Kucheman, Executive Vice President and Group President, Cardiology, Rhythm and Vascular for Boston Scientific.  "As the worldwide prevalence of diabetes continues to increase dramatically, these findings are very encouraging for physicians and their patients."

Diabetes is generally associated with an increased risk of cardiovascular events and patients with diabetes are more likely than non-diabetic patients to require repeat procedures due to a higher incidence of restenosis following angioplasty and stenting.

In March, the Company announced one-year results from its PERSEUS clinical program demonstrating positive safety and efficacy outcomes for the TAXUS Element Stent System compared to prior-generation Boston Scientific stents in more than 1,486 patients in two parallel trials at 90 centers worldwide.  

The TAXUS Element Paclitaxel-Eluting Stent System received CE Mark approval in May, which included a specific indication for the treatment of diabetic patients.  The Company received CE Mark approval for the PROMUS® Element™ Everolimus-Eluting Stent System in October 2009.  Both Element systems incorporate the same platinum chromium alloy, innovative stent design and advanced catheter delivery system.

The Company expects U.S. Food and Drug Administration approval for the TAXUS Element Stent System(4) in mid 2011 and for the PROMUS Element Stent System in mid 2012.  In Japan, the Company expects approval for the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS Element Stent System in mid 2012.

In the U.S., the TAXUS Element (ION) Stent and the PROMUS Element Sten
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... 2011 Mylan Inc. (Nasdaq: MYL ) today announced ... which will resolve litigation related to Lipitor ® Tablets, 10 ... Atorvastatin Calcium Tablets. The terms of the agreement are confidential, and ... of Justice and the Federal Trade Commission. Lipitor had ...
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... Johnson as Chief Executive Officer, effective January 31, 2011.  Mr. ... of directors. Mr. Johnson brings significant biotechnology business ... Vice President of Eli Lilly and Company and President of ...
Cached Medicine Technology:Mylan Announces Lipitor® Settlement Agreement 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 2Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 3Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer 4
(Date:4/24/2014)... better to give than to receive at least if ... suggests. , The study found that 15- and 16-year-olds who ... to family members, are less likely to become depressed than ... keeping the money for themselves. , The researchers detail their ... Sciences . , The study focused on the ventral striatum, ...
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... unrelated donors was safe and effective in treating ... Clostridium difficile , according to a new pilot ... and available online. Known as fecal microbiota transplantation, ... a colonoscope or a nasogastric tube. The findings ... more readily available to patients. , A growing ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... developed a way to detect and measure cancer levels ... with tails of synthetic DNA., A team led by ... gold nanoparticles to target and bind to fragments of ... which can indicate the presence and stage of breast ... a cell can be determined by examining the specific ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... non-recurring event in 2007, net loss stable ... unless otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ ... Canadian,biopharmaceutical company, today announced financial results for the first,quarter ... "We are also focused on the successful completion ...
... HILL, N.C., Nov. 9 Pharmaceutical product teams,have ... of a new product. The problem is,launch teams ... to run,effectively and therefore only produce a sub-optimal ... executives agree that,collaborative behavior and cross-functional team work ...
... New Capital to Support Continued Advancement of Novel Technology and ... ... Anaptys Biosciences, Inc., a,privately-held therapeutic antibody product company, today announced ... led by Novo A/S.,Additional investors participating significantly in the round were ...
... FRANCISCO and CHICO, Calif., Nov. 8 State,Compensation ... health seminar,as part of State Fund,s Employer Education ... State Fund,s Back,Connection(TM). The three-hour seminar entitled "Watch ... shows employers how they,can involve the very people ...
... 8 InteKrin Therapeutics, Inc.,a privately-held clinical stage ... novel drugs for the treatment of,diabetes and cardio-metabolic ... joined the company as Chief Medical Officer. Dr. ... team and will be,responsible for the clinical development ...
... in 2008, OTTAWA, Canada, Nov. 8 ... press release is, http://www.naturalnutritioninc.com . Sports and ... Board: NNTN), http://www.naturalnutritioninc.com has recently expanded ... equipment to produce,sheeted protein and energy bars, ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 2Health News:Pharmaceutical Product Commercialization: Enabling Teams to Excel 3Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 2Health News:Anaptys Biosciences Raises Over $33 Million in Series B Financing 3Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 2Health News:InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer 3Health News:Corrected & Replaced - Natural Nutrition Expands Revenue Capabilities with Newly Installed State of the Art Nutrition Bar Line 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: